Two worthy Stocks to Watch: Range Resources Corp. (RRC), BioDelivery Sciences International, Inc. (BDSI)


Range Resources Corp. (NYSE:RRC)

Stock’s Trading Stats:

Range Resources Corp. (NYSE:RRC) is trading up with a percentage change of 4.44% and is at $33.89 right now. The Company’s market capitalization stands at $5.76 Billion in the current trading Session whereas, its outstanding shares are 169.59 Million.

Recent Press Release:

Range Resources Corp. (RRC) on March 28, 2016 declared that it has accomplished the sale of its Bradford County non-operated assets. After purchase price adjustments based upon a January 1st effective date, Range received about $110 million of sales proceeds at the closing plus retaining the net cash flow since the effective date. In early February, Range signed a purchase and sale agreement covering its non-operating Marcellus interest in Bradford County, Pennsylvania for about $112 million. Range sold an average working interest of 23% covering about 10,900 net acres with net production of about 22 Mmcf per day.

Range will include the Bradford County operations in its operations until the closing date in its first quarter stated operations. The net proceeds were used to reduce debt and other corporate purposes. This monetization further strengthens the Company’s financial position by reducing leverage and enhancing liquidity. After the sale, the borrowing base under Range’s revolving credit facility remains unchanged at $3 billion.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

Stock’s Trading Stats:

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is surging 9.01% percent and is at $3.63 in the Real-Time trading session. The stock’s market capitalization stands at $200.15 Million with outstanding shares of 53.48 Million.

Recent Press Release:

BioDelivery Sciences International, Inc. (BDSI) on March 10, 2016 reported financial results for the fourth quarter and full-year ended December 31, 2015, and reviewed its most significant recent accomplishments and upcoming milestones.

Net revenue for BUNAVAIL buccal film in the fourth quarter raised 29% to $1.5 million contrast to the third quarter of 2015. BUNAVAIL net revenue for the 12-months ended December 31, 2015, was $4.2 million. BREAKYL (brand name for ONSOLIS in the E.U.) revenue for the 12 month period was $1.4 million. BDSI net revenue for the 12-months ended December 31, 2015, was $48.2 million, contrast to $38.9 million in the same period of 2014. This revenue increase was mostly driven by the milestone payment received from Endo Pharmaceuticals upon the U.S. Food and Drug Administration (FDA) approval of BELBUCA™ (buprenorphine) buccal film, which generated $50 million in payments. Thirty ($30) million was attributed to the actual regulatory approval and was earned right away while the additional $20 million was attributed to the extension of patent protection until 2027 from a patent granted in 2012 and payable on the FDA approval of BELBUCA. The latter aspect of the payment will be recognized over the patent extension period.